Kezar Life Sciences (KZR) Stock Forecast, Price Target & Predictions
KZR Stock Forecast
Kezar Life Sciences stock forecast is as follows: an average price target of $17.50 (represents a 174.29% upside from KZR’s last price of $6.38) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
KZR Price Target
The average price target for Kezar Life Sciences (KZR) is $17.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $14.00. This represents a potential 174.29% upside from KZR's last price of $6.38.
KZR Analyst Ratings
According to 3 Wall Street analysts, Kezar Life Sciences's rating consensus is 'Buy'. The analyst rating breakdown for KZR stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Kezar Life Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 12, 2022 | H.C. Wainwright | $21.00 | $9.76 | 115.16% | 229.15% | |
| May 04, 2022 | Wells Fargo | $14.00 | $7.94 | 76.36% | 119.44% |
The latest Kezar Life Sciences stock forecast, released on Aug 12, 2022 by H.C. Wainwright company, set a price target of $21.00, which represents a 115.16% increase from the stock price at the time of the forecast ($9.76), and a 229.15% increase from KZR last price ($6.38).
Kezar Life Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $6.38 | $6.38 | $6.38 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Kezar Life Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Kezar Life Sciences's last price of $6.38. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 02, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Oct 14, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Oct 02, 2024 | H.C. Wainwright | Neutral | Downgrade | |
| Oct 01, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jan 03, 2023 | Wells Fargo | Overweight | Overweight | Hold |
| Jun 28, 2022 | Wells Fargo | Overweight | Overweight | Hold |
Kezar Life Sciences's last stock rating was published by H.C. Wainwright on Dec 02, 2024. The company gave KZR a "Neutral" rating, the same as its previous rate.
Kezar Life Sciences Financial Forecast
Kezar Life Sciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $7.00M |
| Avg Forecast | - | - | - | - | $1.67M | $1.67M | $1.67M | $1.67M | $1.60M | $800.00K | $750.00K | $666.67K | $1.00M | $166.67K |
| High Forecast | - | - | - | - | $1.67M | $1.67M | $1.67M | $1.67M | $1.60M | $800.00K | $750.00K | $666.67K | $1.00M | $166.83K |
| Low Forecast | - | - | - | - | $1.67M | $1.67M | $1.67M | $1.67M | $1.60M | $800.00K | $750.00K | $666.67K | $1.00M | $166.50K |
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.00% |
Kezar Life Sciences's average Quarter revenue forecast for Dec 23 based on 3 analysts is $1.00M, with a low forecast of $1.00M, and a high forecast of $1.00M. KZR's average Quarter revenue forecast represents a -85.71% decrease compared to the company's last Quarter revenue of $7.00M (Sep 23).
Kezar Life Sciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-28.12M | $-25.53M |
| Avg Forecast | - | - | - | - | $1.00M | $1.00M | $1.00M | $1.00M | $960.00K | $480.00K | $450.00K | $400.00K | $600.00K | $100.00K |
| High Forecast | - | - | - | - | $1.00M | $1.00M | $1.00M | $1.00M | $960.00K | $480.00K | $450.00K | $400.00K | $600.00K | $100.10K |
| Low Forecast | - | - | - | - | $1.00M | $1.00M | $1.00M | $1.00M | $960.00K | $480.00K | $450.00K | $400.00K | $600.00K | $99.90K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -46.87% | -255.27% |
undefined analysts predict KZR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kezar Life Sciences's previous annual EBITDA (undefined) of $NaN.
Kezar Life Sciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-32.26M | $-23.10M |
| Avg Forecast | $-224.53M | $-219.01M | $-213.59M | $-208.26M | $-178.03M | $-176.33M | $-181.92M | $-187.27M | $-210.37M | $-229.71M | $-233.26M | $-243.21M | $-276.92M | $-260.10M |
| High Forecast | $-224.53M | $-219.01M | $-213.59M | $-208.26M | $-178.03M | $-176.33M | $-181.92M | $-180.91M | $-201.06M | $-229.71M | $-233.26M | $-243.21M | $-241.42M | $-260.10M |
| Low Forecast | $-224.53M | $-219.01M | $-213.59M | $-208.26M | $-178.03M | $-176.33M | $-181.92M | $-192.92M | $-218.14M | $-229.71M | $-233.26M | $-243.21M | $-305.32M | $-260.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.12% | 0.09% |
Kezar Life Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KZR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Kezar Life Sciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $5.48M | $8.79M |
| Avg Forecast | - | - | - | - | $2.60M | $2.60M | $2.60M | $2.60M | $2.49M | $1.25M | $1.17M | $1.04M | $1.56M | $259.71K |
| High Forecast | - | - | - | - | $2.60M | $2.60M | $2.60M | $2.60M | $2.49M | $1.25M | $1.17M | $1.04M | $1.56M | $259.97K |
| Low Forecast | - | - | - | - | $2.60M | $2.60M | $2.60M | $2.60M | $2.49M | $1.25M | $1.17M | $1.04M | $1.56M | $259.45K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.52% | 33.84% |
Kezar Life Sciences's average Quarter SG&A projection for Mar 24 is $1.04M, based on 1 Wall Street analysts, with a range of $1.04M to $1.04M. The forecast indicates a -81.04% fall compared to KZR last annual SG&A of $5.48M (Dec 23).
Kezar Life Sciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.44 | $-0.32 |
| Avg Forecast | $-3.08 | $-3.00 | $-2.93 | $-2.85 | $-2.44 | $-2.42 | $-2.49 | $-2.57 | $-2.88 | $-3.15 | $-3.20 | $-3.33 | $-3.80 | $-3.56 |
| High Forecast | $-3.08 | $-3.00 | $-2.93 | $-2.85 | $-2.44 | $-2.42 | $-2.49 | $-2.48 | $-2.76 | $-3.15 | $-3.20 | $-3.33 | $-3.31 | $-3.56 |
| Low Forecast | $-3.08 | $-3.00 | $-2.93 | $-2.85 | $-2.44 | $-2.42 | $-2.49 | $-2.64 | $-2.99 | $-3.15 | $-3.20 | $-3.33 | $-4.18 | $-3.56 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.12% | 0.09% |
According to undefined Wall Street analysts, Kezar Life Sciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KZR previous annual EPS of $NaN (undefined).
Kezar Life Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| STTK | Shattuck Labs | $1.15 | $12.00 | 943.48% | Hold |
| NKTX | Nkarta | $2.27 | $21.60 | 851.54% | Buy |
| HOWL | Werewolf Therapeutics | $1.64 | $12.00 | 631.71% | Buy |
| KROS | Keros Therapeutics | $18.00 | $102.00 | 466.67% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| KZR | Kezar Life Sciences | $6.52 | $17.50 | 168.40% | Buy |
| FHTX | Foghorn Therapeutics | $5.51 | $14.00 | 154.08% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| BOLT | Bolt Biotherapeutics | $0.54 | $1.00 | 85.19% | Hold |
| DSGN | Design Therapeutics | $6.25 | $9.67 | 54.72% | Buy |
| NRIX | Nurix Therapeutics | $21.18 | $32.67 | 54.25% | Buy |
| LYEL | Lyell Immunopharma | $0.65 | $1.00 | 53.85% | Hold |
| RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |
| KYMR | Kymera Therapeutics | $42.30 | $58.60 | 38.53% | Buy |
| IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |